Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
Not Confirmed
Not Confirmed
17-20 March, 2025
Antibody EngineeringAntibody Engineering
Not Confirmed
Not Confirmed
15-19 December, 2024
Pharma, Lab & Chemical...Pharma, Lab & Chemical Expo
Not Confirmed
Not Confirmed
03-05 January, 2025
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
Industry Trade Show
Not Confirmed
17-20 March, 2025
Antibody EngineeringAntibody Engineering
Industry Trade Show
Not Confirmed
15-19 December, 2024
Pharma, Lab & Chemical...Pharma, Lab & Chemical Expo
Industry Trade Show
Not Confirmed
03-05 January, 2025
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/translational-pharmaceutics-our-flagship-platform-for-drug-development-empowers-our-clients-with-unparalleled-flexibility
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/cdmo-activity-tracker-bora-polpharma-make-acquisitions-evonik-euroapi-porton-announce-technological-expansions
04 Oct 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/sirnaomics-has-been-subscribed-for-17-527-696-subscription-shares-new-capital-injection-to-promote-business-growth-and-development-302267528.html
19 Sep 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/sirnaomics-announces-demonstration-of-a-novel-mechanism-of-action-of-its-sirna-therapeutics-for-focal-fat-reduction-in-journal-of-cosmetic-dermatology-302252985.html
31 Jul 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/sirnaomics-announces-a-partnership-with-gore-range-capital-for-establishment-of-a-jv-sagesse-bio-to-advance-its-rnai-therapeutics-into-aesthetic-medicine-302211747.html
11 Jul 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/sirnaomics-announces-completion-of-ind-enabling-studies-of-safety-and-efficacy-for-stp125g-with-nhp-models-targeting-apoc3-for-treatment-of-cardiovascular-diseases-302195644.html
28 Jun 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/sirnaomics-announces-completion-of-stp707-phase-i-clinical-study-with-strong-safety-profile-and-disease-activity-for-the-treatment-of-pancreatic-cancer-patients-302185472.html
12 Jun 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/sirnaomics-demonstrates-strong-antitumor-activity-of-its-novel-oligonucleotide-chemodrug-conjugate-in-journal-of-oncology-research-and-therapy-302171871.html
Details:
The partnership with Sagesse will rapidly advance Sirnaomics' lead product STP705 (Pixofisiran/Lixadesiran) that targets TGF-ß1/COX-2. It is being evaluated to address body contouring & fat reduction.
Lead Product(s): Pixofisiran,Lixadesiran
Therapeutic Area: Dermatology Brand Name: STP705
Study Phase: Phase IProduct Type: Large molecule
Sponsor: Sagesse Bio
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership July 31, 2024
Lead Product(s) : Pixofisiran,Lixadesiran
Therapeutic Area : Dermatology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Sagesse Bio
Deal Size : Undisclosed
Deal Type : Partnership
Sirnaomics Partners with Gore Range to Establish JV Sagesse Bio for RNAi Therapeutics
Details : The partnership with Sagesse will rapidly advance Sirnaomics' lead product STP705 (Pixofisiran/Lixadesiran) that targets TGF-ß1/COX-2. It is being evaluated to address body contouring & fat reduction.
Brand Name : STP705
Molecule Type : Large molecule
Upfront Cash : Undisclosed
July 31, 2024
Details:
STP125G is a single-stranded siRNA therapeutics targeting ApoC3 mRNA, based on Sirnaomics proprietary GalAhead™ mxRNA technology.
Lead Product(s): STP125G
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: STP125G
Study Phase: IND EnablingProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 11, 2024
Lead Product(s) : STP125G
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : IND Enabling
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Sirnaomics Completes IND-Enabling Studies of STP125G for Cardiovascular Diseases
Details : STP125G is a single-stranded siRNA therapeutics targeting ApoC3 mRNA, based on Sirnaomics proprietary GalAhead™ mxRNA technology.
Brand Name : STP125G
Molecule Type : Large molecule
Upfront Cash : Not Applicable
July 11, 2024
Details:
STP122G is a GalNAc-based RNAi therapeutic, SC formulation, targetting Factor XI. It is in early-stage development as an anticoagulant, utilizing company's proprietary GalAhead platform.
Lead Product(s): STP122G
Therapeutic Area: Hematology Brand Name: STP122G
Study Phase: Phase IProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 08, 2024
Lead Product(s) : STP122G
Therapeutic Area : Hematology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Sirnaomics Reports Positive Results for GalNAc-Based RNAi Therapeutic STP122G
Details : STP122G is a GalNAc-based RNAi therapeutic, SC formulation, targetting Factor XI. It is in early-stage development as an anticoagulant, utilizing company's proprietary GalAhead platform.
Brand Name : STP122G
Molecule Type : Large molecule
Upfront Cash : Not Applicable
July 08, 2024
Details:
STP707 is composed of two siRNA oligonucleotides, targeting TGF-β1 and COX-2 mRNA respectively. It is being evaluated for the treatment of solid tumors.
Lead Product(s): STP707
Therapeutic Area: Oncology Brand Name: STP707
Study Phase: Phase IProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 28, 2024
Sirnaomics Completes STP707 Phase I Study with Strong Safety Profile in Pancreatic Cancer
Details : STP707 is composed of two siRNA oligonucleotides, targeting TGF-β1 and COX-2 mRNA respectively. It is being evaluated for the treatment of solid tumors.
Brand Name : STP707
Molecule Type : Large molecule
Upfront Cash : Not Applicable
June 28, 2024
Details:
RV-1770 is an innovative mRNA-based vaccine formulation with a unique AI-enhanced design using the sequence of the recent RSV clinical isolate. It demonstrated immunogenic responses and neutralization against both type A and B strains of RSV in preclinical cotton rat studies.
Lead Product(s): RV-1770
Therapeutic Area: Infections and Infectious Diseases Brand Name: RV-1770
Study Phase: IND EnablingProduct Type: Vaccine
Recipient: RNAimmune
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 18, 2023
Lead Product(s) : RV-1770
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : IND Enabling
Recipient : RNAimmune
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : RV-1770 is an innovative mRNA-based vaccine formulation with a unique AI-enhanced design using the sequence of the recent RSV clinical isolate. It demonstrated immunogenic responses and neutralization against both type A and B strains of RSV in preclinic...
Brand Name : RV-1770
Molecule Type : Vaccine
Upfront Cash : Not Applicable
December 18, 2023
Details:
STP707 is composed of two siRNA oligonucleotides, targeting TGF-β1 and COX-2 mRNA respectively, formulated in nanoparticles with a Histidine-Lysine Co-Polymer (HKP+H) peptide as the carrier, used for the treatment of Multiple Solid Tumors.
Lead Product(s): STP707
Therapeutic Area: Oncology Brand Name: STP707
Study Phase: Phase IProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 30, 2023
Details : STP707 is composed of two siRNA oligonucleotides, targeting TGF-β1 and COX-2 mRNA respectively, formulated in nanoparticles with a Histidine-Lysine Co-Polymer (HKP+H) peptide as the carrier, used for the treatment of Multiple Solid Tumors.
Brand Name : STP707
Molecule Type : Large molecule
Upfront Cash : Not Applicable
August 30, 2023
Details:
The partnership accelerates EDIRNA's proprietary Edit-to-Cure Therapeutics™ platform for RNA-Editing therapeutics, targeting diseases with high unmet clinical needs.
Lead Product(s): RNA-editing Therapeutic
Therapeutic Area: Rare Diseases and Disorders Brand Name: Undisclosed
Study Phase: Discovery PlatformProduct Type: Large molecule
Recipient: EDIRNA
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership July 05, 2023
Lead Product(s) : RNA-editing Therapeutic
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Discovery Platform
Recipient : EDIRNA
Deal Size : Undisclosed
Deal Type : Partnership
Details : The partnership accelerates EDIRNA's proprietary Edit-to-Cure Therapeutics™ platform for RNA-Editing therapeutics, targeting diseases with high unmet clinical needs.
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Undisclosed
July 05, 2023
Details:
STP705, is a small interfering RNA therapeutic that takes advantage of a dual-targeted inhibitory property and polypeptide nanoparticle (PNP)-enhanced delivery to directly knock TGF-β1 and COX-2 gene expression, which being investigated for Squamous Cell Carcinoma in situ.
Lead Product(s): STP705
Therapeutic Area: Oncology Brand Name: STP705
Study Phase: Phase IIProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 19, 2023
Details : STP705, is a small interfering RNA therapeutic that takes advantage of a dual-targeted inhibitory property and polypeptide nanoparticle (PNP)-enhanced delivery to directly knock TGF-β1 and COX-2 gene expression, which being investigated for Squamous Cel...
Brand Name : STP705
Molecule Type : Large molecule
Upfront Cash : Not Applicable
June 19, 2023
Details:
STP705, is a siRNA (small interfering RNA) therapeutic that takes advantage of a dual-targeted inhibitory property and polypeptide nanoparticle (PNP)-enhanced delivery to directly knock TGF-β1 and COX-2 gene expression, which being investigated for Abdominoplasty.
Lead Product(s): STP705
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Brand Name: STP705
Study Phase: Phase IProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 05, 2023
Lead Product(s) : STP705
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : STP705, is a siRNA (small interfering RNA) therapeutic that takes advantage of a dual-targeted inhibitory property and polypeptide nanoparticle (PNP)-enhanced delivery to directly knock TGF-β1 and COX-2 gene expression, which being investigated for Abdo...
Brand Name : STP705
Molecule Type : Large molecule
Upfront Cash : Not Applicable
June 05, 2023
Details:
STP122G, Sirnaomics' leading RNAi drug candidate, is a siRNA that targets Factor XI and first participant Dosed in a Phase I clinical trial for prevention and treatment of stroke after atrial fibrillation.
Lead Product(s): STP122G
Therapeutic Area: Hematology Brand Name: STP122G
Study Phase: Phase IProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 01, 2023
Lead Product(s) : STP122G
Therapeutic Area : Hematology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : STP122G, Sirnaomics' leading RNAi drug candidate, is a siRNA that targets Factor XI and first participant Dosed in a Phase I clinical trial for prevention and treatment of stroke after atrial fibrillation.
Brand Name : STP122G
Molecule Type : Large molecule
Upfront Cash : Not Applicable
June 01, 2023
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?